{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:30:54Z","timestamp":1774362654817,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001415","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T00:00:00Z","timestamp":1374710400000}}],"reference-count":25,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001415.pub2","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T18:06:07Z","timestamp":1374775567000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gabapentin add-on for drug-resistant partial epilepsy"],"prefix":"10.1002","author":[{"given":"Sarah","family":"Al-Bachari","sequence":"first","affiliation":[{"name":"Royal Preston Hospital; Department of Neurology; Sharoe Green Lane North Fulwood Preston Lancashire UK PR2 9HT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Pulman","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"University of Warwick; Department of Statistics; Coventry UK CV4 7AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,25]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD001415.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1528-1157.1994.tb02513.x","article-title":"Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study","volume":"35","author":"Anhut","year":"1994","journal-title":"Epilepsia"},{"issue":"8","key":"10.1002\/14651858.CD001415.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1528-1157.1999.tb00833.x","article-title":"Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.56.6.743","article-title":"Rapid Initiation of gabapentin: a randomised control trial","volume":"56","author":"Fisher","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.62.4.372","article-title":"Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy","volume":"62","author":"Leach","year":"1997","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD001415.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1528-1157.2000.tb04607.x","article-title":"Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study","volume":"41","author":"Lindberger","year":"2000","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001415.pub2-BIB0006|cit6","first-page":"359","article-title":"Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine","volume":"50","author":"Sethi","year":"2002","journal-title":"Neurology India"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1991.tb04689.x","article-title":"Double blind study of gabapentin in the treatment of partial seizures","volume":"32","author":"Sivenius","year":"1991","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD001415.pub2-BIB0008|cit8","first-page":"151","article-title":"Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy","volume":"56","author":"Tomovic","year":"1999","journal-title":"Vojnosanitetski Pregled"},{"issue":"8698","key":"10.1002\/14651858.CD001415.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0140-6736(90)91123-R","article-title":"Gabapentin in partial epilepsy","volume":"335","author":"UK Gabapentin Study Group","year":"1990","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD001415.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1212\/WNL.43.11.2292","article-title":"Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study","volume":"43","author":"The US Gabapentin Study Group No 5","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1440-1819.2006.01553.x","article-title":"Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study","volume":"60","author":"Yamauchi","year":"2006","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"6","key":"10.1002\/14651858.CD001415.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jnnp.50.6.682","article-title":"Gabapentin as an antiepileptic drug in man","volume":"50","author":"Crawford","year":"1987","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"Suppl","key":"10.1002\/14651858.CD001415.pub2-BIB0013|cit13","first-page":"69","article-title":"A double blind study of gabapentin in partial seizures","volume":"41","author":"Kwan","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD001415.pub2-BIB0014|cit14","first-page":"106","article-title":"Gabapentin as add-on therapy for refractory partial seizures in children 1-36 months of age: a novel, short-term, placebo-controlled trial","volume":"41","author":"Shapiro","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0015|cit15","unstructured":"British National Formulary http:\/\/www.bnf.org\/bnf\/org_450080.htm"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the national general practice study of epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0018|cit18","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD001415.pub2-BIB0020|cit20","first-page":"72","article-title":"Gabapentin","volume":"36 Suppl","author":"McClean","year":"1995","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0021|cit21","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1157.1981.tb06158.x","article-title":"Phenytoin for epilepsy: a long term prospective study, assisted by serum level monitoring in previously untreated patients","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.313.7066.1169","article-title":"New antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"313","author":"Marson","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001415.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001415","article-title":"Gabapentin add-on for drug-resistant partial epilepsy","author":"Marson","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001415.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001415.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:02:45Z","timestamp":1628542965000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001415.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,25]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001415.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001415.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,25]]}}}